Human Neuralized is a novel tumour suppressor targeting Wnt/β-catenin signalling in colon cancer

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Epigenetically silenced genes in cancer are often tumor suppressor candidates, but their roles are not fully understood.
• The Wnt/β-catenin signaling pathway is frequently dysregulated in various human cancers, driving tumor progression.

Purpose of the Study:

• To identify novel tumor suppressors involved in regulating oncogenic signaling pathways.
• To investigate the role of human Neuralized (NEURL) in cancer, specifically its interaction with Wnt/β-catenin signaling.

Main Methods:

• Gene expression analysis in human colorectal cancer tissues.
• Functional assays to determine NEURL's role as an E3 ubiquitin ligase.
• Co-immunoprecipitation to study protein-protein interactions between NEURL and β-catenin.

Main Results:

• NEURL expression is epigenetically regulated and significantly suppressed in human colorectal cancer.
• NEURL directly interacts with oncogenic β-catenin and mediates its degradation.
• NEURL functions as an E3 ubiquitin ligase, reducing cytoplasmic β-catenin levels independently of GSK3β and β-TrCP.
• NEURL's tumor suppressive function is dependent on the degradation of oncogenic β-catenin.

Conclusions:

• Human Neuralized (NEURL) is a novel tumor suppressor targeting the Wnt/β-catenin pathway.
• NEURL acts by directly degrading oncogenic β-catenin through its E3 ubiquitin ligase activity.
• NEURL represents a potential therapeutic target for human cancers driven by Wnt/β-catenin signaling.